-
Peptide news — July 2026 roundupThe GLP-1 pill era arrives with orforglipron (Foundayo); Amgen's MariTide moves deeper into Phase 3; the FDA compounding vote lands 23–24 July; and the UK line holds. Two new Frontier entries added.
-
Peptide news — May to June 2026 roundupThe July PCAC agenda is now firm — BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and DSIP under formal review. Plus an early neuroprotection readout, the Peptide World Congress, and the unchanged UK position.
-
Peptide news — April to May 2026 roundupFDA reclassification status, Lilly retatrutide trial cascade, MBX / Innovent / Boehringer pipeline announcements, community protocol shifts, UK MHRA position, safety signals. Publishing Mon 25 May.
About PeptideWorld
PeptideWorld is Pep IQ's fortnightly news digest — a single place to catch the peptide regulatory, scientific, and community developments worth knowing from the last few weeks. Bullet-pointed headlines, sourced claims, conditional voice where evidence is still developing.
New digests publish to the pinned card at the top of the Pep IQ blog. Past digests are archived here, each at its own date-stamped URL.
This archive is young — May 2026 was the first digest, June 2026 the second. The roundup grows from here.